The estimated Net Worth of Mark A Goldsmith is at least $31.7 millió dollars as of 1 August 2024. Mark Goldsmith owns over 10,000 units of Revolution Medicines Inc stock worth over $13,409,729 and over the last 6 years he sold RVMD stock worth over $13,681,825. In addition, he makes $4,576,250 as Chairman of the Board, President és Chief Executive Officer at Revolution Medicines Inc.
Mark has made over 34 trades of the Revolution Medicines Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 10,000 units of RVMD stock worth $40,900 on 1 August 2024.
The largest trade he's ever made was selling 113,133 units of Revolution Medicines Inc stock on 28 September 2020 worth over $3,871,411. On average, Mark trades about 14,158 units every 35 days since 2018. As of 1 August 2024 he still owns at least 321,885 units of Revolution Medicines Inc stock.
You can see the complete history of Mark Goldsmith stock trades at the bottom of the page.
Dr. Mark A. Goldsmith M.D. Ph.D. was Director of the Company. serves as Founding President, Chief Executive Officer, Board Director of the Company. After studying biology and science in human affairs at Princeton University, he pursued a dual career in clinical medicine and scientific research through the Medical Scientist Training Program at the University of California San Francisco (UCSF). After postgraduate training at the Brigham and Women’s Hospital/Harvard Medical School and UCSF, Mark joined the faculty of the UCSF School of Medicine, led a dynamic research laboratory within the Gladstone Institute of Virology and Immunology focused on the pathogenesis of and discovery of new treatments for life-threatening viral diseases, and taught and practiced medicine at the San Francisco General Hospital/UCSF. He co-authored 85 scientific publications and is co-inventor on multiple issued patents and applications. He also served as assistant director of the Gladstone Institute of Virology and Immunology and was consultant and collaborator to a variety of small and large biotechnology and pharmaceutical companies. After a productive career in academia, he was recruited to the private sector, where he served in senior management roles in private and public biotechnology companies, including Genencor International and Constellation Pharmaceuticals, where he drove the development of an industry-leading strategic alliance with Genentech, a member of the Roche Group. Prior to REVOLUTION Medicines, he served as chief executive officer of four companies spanning early discovery through full development. He also served as senior executive-in-residence at Prospect Venture Partners. Since 2012 Mark has been a partner in Third Rock Ventures and leader of its West Coast operations. He holds an A.B. from Princeton University and an M.D. and Ph.D. in microbiology and immunology from UCSF.
As the Chairman of the Board, President és Chief Executive Officer of Revolution Medicines Inc, the total compensation of Mark Goldsmith at Revolution Medicines Inc is $4,576,250. There are no executives at Revolution Medicines Inc getting paid more.
Mark Goldsmith is 58, he's been the Chairman of the Board, President és Chief Executive Officer of Revolution Medicines Inc since 2014. There are 4 older and 9 younger executives at Revolution Medicines Inc. The oldest executive at Revolution Medicines Inc is Elizabeth Anderson, 62, who is the Independent Director.
Mark's mailing address filed with the SEC is C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY, CA, 94063.
Over the last 5 years, insiders at Revolution Medicines Inc have traded over $249,645,422 worth of Revolution Medicines Inc stock and bought 3,371,315 units worth $74,500,278 . The most active insiders traders include Peter Svennilson, Thilo Schroeder és Rock Ventures Ii, L.P.Third.... On average, Revolution Medicines Inc executives and independent directors trade stock every 11 days with the average trade being worth of $3,075,216. The most recent stock trade was executed by Stephen Michael Kelsey on 13 August 2024, trading 16,667 units of RVMD stock currently worth $68,168.
revolution medicines discovers and develops new drugs that harness the therapeutic potential of frontier oncology targets on behalf of cancer patients. our innovative product engine draws inspiration from nature and evolution, which offer insights into cancer targets, disease mechanisms and therapeutic approaches. we pay particular attention to natural products that are inherently rich with biological function as a result of natural selection and can inform and guide our discovery and development of small molecules that can modulate these targets.
Revolution Medicines Inc executives and other stock owners filed with the SEC include: